Market Spotlight: Sarcoma
Market Spotlight: Sarcoma
This Market Spotlight report covers the Sarcoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2017, there were approximately 413,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 485,100 incident cases by 2026.
- Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (83%), while a smaller proportion were osteosarcomas and other malignant bone tumors (17%).
- The approved drugs in the sarcoma space focus on targets such as tumor necrosis factor-alpha, microtubules, platelet-derived growth factor receptor, KIT/c-KIT, vascular endothelial growth factor receptor, and DNA. All of the approved drugs are administered via the intravenous route, except for Votrient, which is an oral drug.
- The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intratumoral, and topical formulations.
- • High-impact upcoming events in the sarcoma space comprise topline Phase III trial results for TRC105. The overall likelihood of approval of a Phase I sarcoma asset is 13.6%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 18 licensing and asset acquisition deals involving sarcoma drugs during 2013–18. The licensing agreement between Adaptimmune and GlaxoSmithKline in 2014 for $1,150m, to develop and commercialize NY-ESO-1(C259), was the largest deal during the period.
- The clinical trials distribution across Phase I–IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.
- The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major EU markets, while Israel has the top spot in Asia.
- Clinical trial activity in the sarcoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for sarcoma, with 15 trials.
- Merck & Co leads industry sponsors with the highest number of overall clinical trials for sarcoma, followed by Novartis and Pfizer.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 Radiation therapy
9 Targeted therapies
11 Epidemiological disease definition
17 MARKETED DRUGS
21 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Yondelis for Sarcoma (June 04, 2018)
29 Selinexor for Sarcoma (June 01, 2018)
30 Selinexor for Sarcoma (September 20, 2017)
32 Selinexor for Sarcoma (March 10, 2017)
33 Tivantinib for Sarcoma (February 17, 2017)
35 KEY UPCOMING EVENTS
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 NantCell gets exclusive aldoxorubicin rights from CytRx
39 PARENT PATENTS
40 REVENUE OPPORTUNITY
41 CLINICAL TRIAL LANDSCAPE
42 Sponsors by status
43 Sponsors by phase
46 Prescription information
LIST OF FIGURES
14 Figure 1: Trends in incident cases of sarcoma, 2017–26
15 Figure 2: Incident cases of sarcoma, by age, 2017
16 Figure 3: Incident cases of sarcoma, by tumor type, 2017
21 Figure 4: Overview of pipeline drugs for sarcoma in the US
21 Figure 5: Pipeline drugs for sarcoma, by company
22 Figure 6: Pipeline drugs for sarcoma, by drug type
22 Figure 7: Pipeline drugs for sarcoma, by classification
29 Figure 8: Yondelis for Sarcoma (June 04, 2018): Phase III – TSAR
30 Figure 9: Selinexor for Sarcoma (June 01, 2018): Phase II/III – SEAL
32 Figure 10: Selinexor for Sarcoma (September 20, 2017): Phase II/III – SEAL
34 Figure 11: Tivantinib for Sarcoma (February 17, 2017)
35 Figure 12: Key upcoming events in sarcoma
36 Figure 13: Probability of success in the sarcoma pipeline
37 Figure 14: Licensing and asset acquisition deals in sarcoma, 2013–18
39 Figure 15: Parent patents in sarcoma
41 Figure 16: Clinical trials in sarcoma
41 Figure 17: Top 10 drugs for clinical trials in sarcoma
42 Figure 18: Top 10 companies for clinical trials in sarcoma
42 Figure 19: Trial locations in sarcoma
43 Figure 20: Sarcoma trials status
44 Figure 21: Sarcoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of sarcoma, 2017–26
18 Table 2: Marketed drugs for sarcoma
20 Table 3: Approvals by country for sarcoma
23 Table 4: Pipeline drugs for sarcoma in the US
28 Table 5: Yondelis for Sarcoma (June 04, 2018)
29 Table 6: Selinexor for Sarcoma (June 01, 2018)
31 Table 7: Selinexor for Sarcoma (September 20, 2017)
32 Table 8: Selinexor for Sarcoma (March 10, 2017)
33 Table 9: Tivantinib for Sarcoma (February 17, 2017)
40 Table 10: Historical global sales, by drug ($m), 2013–17
40 Table 11: Forecasted global sales, by drug ($m), 2018–22
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.